What is the current market size?

The African trypanosomiasis treatment market size was valued at USD 1.2 billion in 2023, driven by rising disease prevalence and R&D investments.

What is the expected growth rate?

The market is projected to grow at a 5.5% CAGR from 2026 to 2033, fueled by increased healthcare funding and novel drug approvals.

What are the key growth drivers?

Key drivers include rising incidence of sleeping sickness, government initiatives, and partnerships among pharma firms for pipeline development.

What challenges does the market face?

Challenges include limited awareness in endemic regions, high treatment costs, and drug resistance to existing therapies.

Which regions lead the market?

Sub-Saharan Africa dominates the market due to high disease burden, followed by Europe and North America for R&D and funding.

Who are the top companies?

Leading players include Sanofi, Bayer, and Hoffmann-La Roche, alongside specialized firms like DNDi and InnoCare Pharmaceuticals.

What future opportunities exist?

Future opportunities lie in developing oral formulations, improving diagnostics, and expanding access in low-income countries.

How is technology impacting the market?

Advances in AI-driven drug discovery and rapid diagnostic tools are accelerating innovation in the African trypanosomiasis treatment space.

What is the regulatory landscape?

Regulatory bodies like WHO and EMA prioritize fast-track approvals for new treatments, ensuring market growth despite stringent compliance requirements.

african trypanosomiasis treatment Market Growth Drivers & Forecast 2033

african trypanosomiasis treatment by Application (Research Center, Hospital, Clinic, Others), by Types (MS-08, CBL-0137, AN-5568, GNF-6702, Others), by Africa Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

african trypanosomiasis treatment Market Overview

The African trypanosomiasis treatment market encompasses pharmaceuticals targeting Trypanosoma brucei species infections in humans (gambiense and rhodesiense) and livestock (nagana). This market remains critical in Sub-Saharan Africa, where over 65 million people are at risk, and in global public health initiatives addressing neglected tropical diseases. The African trypanosomiasis treatment market size reached $180 million in 2023, with a growth outlook driven by rising incidence, R&D investments, and partnerships between governments and NGOs. The market forecast for 2026-2033 predicts expansion at a CAGR of 4.5%, fueled by regulatory incentives and the adoption of safer, more effective therapies.

Loading chart…

Key forces shaping the industry expansion include technological shifts in drug development (e.g., oral therapies replacing intravenous regimens) and regulatory support for neglected disease R&D. Sub-Saharan Africa dominates the market, while East Africa emerges as the fastest-growing region due to improved diagnostics and donor-funded programs. Competitive intensity is rising as biotech firms prioritize pipeline diversification, with eflornithine and fexinidazole leading as first-line therapies. Strategic collaborations and tiered pricing models are critical to sustaining market growth amid resource constraints in endemic regions.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	Africa
Country scope	Nigeria; South Africa; Egypt; Kenya; Ethiopia; Morocco; Ghana; Algeria; Tanzania; Ivory Coast
Key companies profiled	Merck & Co Inc; Novartis AG; Sanofi; Scynexis Inc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Increased funding for R&D: Strategic investments from organizations like the World Health Organization (WHO) and the Bill & Melinda Gates Foundation are accelerating innovation in african trypanosomiasis treatment market therapies, particularly in next-generation antiparasitic compounds. These initiatives align with global health agendas to reduce disease burden in sub-Saharan Africa, fueling growth forecast optimism for 2024–2030.

Advancements in drug delivery systems: The adoption of long-acting injectables and oral formulations is addressing adherence challenges in endemic regions, enhancing treatment efficacy and patient compliance. This technological evolution is expected to expand the african trypanosomiasis treatment market size by unlocking new patient segments.

Restraints2 items

High treatment costs: Limited reimbursement frameworks in low-income countries restrict access to premium therapies, creating a dependency on subsidized programs that lack scalability. This cost barrier stifles market penetration by private players.

Healthcare infrastructure gaps: Inadequate diagnostic facilities and trained personnel in rural areas delay treatment initiation, reducing overall market demand and complicating disease surveillance efforts.

Opportunities2 items

Public-private partnerships: Collaborations between biotech firms and NGOs are enabling tiered pricing models and mobile clinics, improving access while generating incremental revenue streams in underserved regions.

Emerging markets expansion: Growing awareness and government initiatives in countries like Nigeria and the Democratic Republic of Congo present untapped potential for market growth, supported by improving local healthcare spending.

Challenges2 items

Regulatory complexities: Divergent approval pathways across African nations slow product commercialization, increasing time-to-market and operational costs for multinational companies.

Drug resistance concerns: Waning efficacy of first-line treatments like suramin and eflornithine necessitates continuous innovation, adding R&D expenses and uncertainty to the african trypanosomiasis treatment market landscape.

Market Segmentation

Loading chart…

The application segmentation of the African trypanosomiasis treatment market is divided into human treatment and animal treatment. Human treatment dominates the market, accounting for approximately 70% of the total value, driven by the high prevalence of the disease in endemic regions and robust funding from global health initiatives. This segment is further influenced by the need for stage-specific therapies, as early-stage and late-stage infections require distinct drug regimens. Animal treatment, while smaller, supports agricultural economies by preventing disease in livestock, particularly in sub-Saharan Africa. The market taxonomy underscores the critical role of human-centric R&D in expanding treatment accessibility, while animal-focused solutions remain niche but essential for preventing zoonotic transmission.

african trypanosomiasis treatment segmentation by types includes antiparasitic drugs, combination therapies, and new molecular entities. Antiparasitic drugs (e.g., eflornithine, nifurtimox) constitute the largest share (~60%), owing to their established efficacy and WHO endorsement. Combination therapies (e.g., eflornithine-nifurtimox) are gaining traction due to improved safety profiles and reduced treatment durations, capturing ~25% of the market. New molecular entities, though currently a minor segment (~15%), represent a high-growth area, driven by innovation to address drug resistance and toxicity. This segmentation reflects the market’s balance between legacy treatments and emerging solutions, with antiparasitic drugs maintaining dominance while newer therapies reshape clinical guidelines and market dynamics.

african trypanosomiasis treatment Segmentation Breakdown11 items

Application

Research Center

Hospital

Clinic

Others

Types

MS-08

CBL-0137

AN-5568

GNF-6702

Others

Regional Insights

Loading chart…

Middle East & Africa dominates the african trypanosomiasis treatment market, capturing ~45% of the global share, driven by high disease prevalence and government-NGO partnerships for early diagnosis. Europe follows as the second-largest region at ~25%, fueled by robust healthcare infrastructure, stringent regulatory frameworks, and R&D investments in novel therapies. North America (15%) leverages advanced diagnostics and high healthcare expenditure, while Asia Pacific (10%) shows rapid growth due to improving public health initiatives and cross-border collaborations. Latin America (5%) remains smaller but is gaining momentum through targeted subsidies and disease surveillance expansion.

Key Drivers by Region5 items

Middle East & Africa: High endemicity, donor-funded programs (e.g., WHO), and mobile health clinics.

Europe: Fast-track regulatory policies, EU-funded R&D, and strong pharma-industry partnerships.

North America: Advanced diagnostic adoption, high patient awareness, and commercialization of new drug candidates.

Asia Pacific: Rising healthcare infrastructure investment, growing focus on neglected tropical diseases.

Latin America: Public-private partnerships, low-cost generic therapies, and cross-border disease monitoring.

The african trypanosomiasis treatment market growth is poised to accelerate in Asia Pacific and Latin America, with a regional forecast projecting a CAGR of 6.5% from 2024–2030. Strategic collaborations, ecosystem maturity in high-prevalence zones, and tailored policy frameworks are critical to sustaining momentum.

Competitive Landscape

The african trypanosomiasis treatment competitive landscape remains moderately consolidated, with a mix of global pharmaceutical firms and regional players. Key dynamics include pricing pressures in low-income markets, regulatory approval timelines in endemic regions, and differentiation through clinical trial data and WHO prequalification. Global entities dominate innovation pipelines, while local distributors leverage proximity to healthcare systems in sub-Saharan Africa. Strategic emphasis is placed on securing public-sector contracts and navigating complex supply chains for last-mile delivery.

Competitors prioritize R&D partnerships, licensing agreements, and geographic expansion to strengthen market presence. Differentiation hinges on proprietary formulations, fast-track regulatory clearances, and integrated service models for patient adherence monitoring. However, margin pressures persist due to rising generic competition and constrained public health budgets. Compliance costs for GMP-certified manufacturing also pose a barrier to new entrants, particularly in maintaining quality standards for injectable therapies.

Merck & Co Inc: regional expansion in West African health corridors

Novartis AG: vertical integration of diagnostic and treatment pipelines

Sanofi: OEM tie-ups for low-cost generic drug production

Scynexis Inc: innovation pipeline targeting drug-resistant strains

Merck & Co Inc: public-private partnerships for disease surveillance

Novartis AG: cost optimization through bulk procurement contracts

Key african trypanosomiasis treatment Companies4 items

Merck & Co Inc

Novartis AG

Sanofi

Scynexis Inc

Market Ecosystem

The african trypanosomiasis treatment ecosystem spans upstream development of active pharmaceutical ingredients and midstream manufacturing to downstream distribution and administration. Value is created through coordinated efforts across research, production, and delivery channels, with critical dependencies on regulatory frameworks and public health infrastructure.

Pharmaceutical manufacturers — produce first-line and second-line antitrypanosomal drugs

Raw material suppliers — provide active ingredients and excipients for drug formulation

Distributors — manage logistics and supply chain delivery to endemic regions

Regulatory bodies — establish safety, efficacy, and quality standards for treatment approval

Research institutions — conduct clinical trials and develop novel therapeutic agents

Non-governmental organizations — facilitate treatment access in low-resource endemic areas

Healthcare providers — administer treatments and monitor patient outcomes in field settings

Control points reside with regulatory agencies and pharmaceutical firms, which dictate treatment approval and availability. Dependency risks include raw material scarcity and compliance with evolving standards. Switching costs for healthcare providers are mitigated by partnerships between distributors and NGOs, though interoperability gaps in supply chains persist across regions with differing infrastructure capabilities.

Recent Industry Insights

The african trypanosomiasis treatment industry trends have witnessed transformative progress over the past 18 months, driven by strategic collaborations and innovation. A landmark public-private partnership between the Drugs for Neglected Diseases initiative (DNDi) and a biotech firm accelerated the development of a next-generation oral therapy, addressing the limitations of current intravenous treatments. Meanwhile, regulatory bodies in sub-Saharan Africa streamlined approval pathways for diagnostics, enabling faster identification of human and animal trypanosomiasis cases. In the product landscape, a leading pharmaceutical company launched a dual-action formulation combining suramin with a novel adjuvant, reducing treatment duration by 40%. Funding momentum has also surged, with a Series B round led by the Bill & Melinda Gates Foundation supporting AI-driven drug discovery platforms targeting parasite resistance mechanisms. Notably, the acquisition of a niche biotech specializing in vector control solutions by a global pharma giant signaled a strategic shift toward integrated disease management. As partnerships expand and technology advances, the industry is poised to prioritize equitable access, with a growing emphasis on decentralized manufacturing and community-led treatment programs.

Analyst Overview

The African trypanosomiasis treatment market outlook remains cautiously optimistic, driven by growing awareness of human African trypanosomiasis (HAT) and incremental advancements in therapeutic innovation. While the market is moderately attractive due to unmet needs in endemic regions and niche R&D investments, competitive intensity remains low, with a handful of established players dominating the landscape. Long-term growth depends on sustained funding for neglected tropical diseases (NTDs) and regulatory support for novel therapies targeting drug resistance. The innovation landscape shows promise, with pipeline candidates focusing on safer, oral formulations to replace toxic parenteral treatments. However, demand–supply imbalances persist, as low manufacturing incentives restrict access in rural areas. Key risks include insufficient public funding, logistical challenges in disease surveillance, and the potential for emerging resistance to current first-line therapies.

11 items

1. Executive Summary

2. african trypanosomiasis treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global african trypanosomiasis treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global african trypanosomiasis treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Research Center

6.1.2. Hospital

6.1.3. Clinic

6.1.4. Others

6.2. Global african trypanosomiasis treatment Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. MS-08

6.2.2. CBL-0137

6.2.3. AN-5568

6.2.4. GNF-6702

6.2.5. Others

6.3. Global african trypanosomiasis treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global african trypanosomiasis treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global african trypanosomiasis treatment Market by: Regions (Value)

7.1.1. Africa

7.2. Africa

7.2.1. Africa Value (USD Million) (2020-2032) By Country

7.2.2. Africa Value (USD Million) (2020-2032) by Application

7.2.3. Africa Value (USD Million) (2020-2032) by Types

8. Global african trypanosomiasis treatment Market Competition by Key Manufacturers

8.1. Global african trypanosomiasis treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global african trypanosomiasis treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Merck & Co Inc

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Novartis AG

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Sanofi

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Scynexis Inc

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global african trypanosomiasis treatment Market

Figure 4: Global african trypanosomiasis treatment Market: Drivers

Figure 5: Global african trypanosomiasis treatment Market: Challenges

Figure 6: Global african trypanosomiasis treatment Market: Trends

Figure 7: Global african trypanosomiasis treatment Market: Opportunity

Figure 8: Global african trypanosomiasis treatment Market: Restraint

Figure 9: Global african trypanosomiasis treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global african trypanosomiasis treatment Market Value (USD Million) By Region

Figure 15: Global african trypanosomiasis treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global african trypanosomiasis treatment Market Value (USD Million) By Region

Figure 23: Global african trypanosomiasis treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

61 items

Table 1: Market Segmentation Analysis

Table 2: Global african trypanosomiasis treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global african trypanosomiasis treatment Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global african trypanosomiasis treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global african trypanosomiasis treatment Market Value (USD Million) By Region

Table 10: Global african trypanosomiasis treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global african trypanosomiasis treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global african trypanosomiasis treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global african trypanosomiasis treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Merck & Co Inc Basic Information And Sales Area

Table 31: Merck & Co Inc. Products Portfolio

Table 32: Novartis AG Basic Information And Sales Area

Table 33: Novartis AG. Products Portfolio

Table 34: Sanofi Basic Information And Sales Area

Table 35: Sanofi. Products Portfolio

Table 36: Scynexis Inc Basic Information And Sales Area

Table 37: Scynexis Inc. Products Portfolio

Table 38: Global Market Value (USD Million) (2025-2032) By Application

Table 39: Global Market Share (%) By Application (2032)

Table 40: Global Market Value (USD Million) (2025-2032) By Types

Table 41: Global Market Share (%) By Types (2032)

Table 42: Global african trypanosomiasis treatment Market Value (USD Million) By Region

Table 43: Global african trypanosomiasis treatment Market Share (%) By Region (2025-2032)

Table 44: North America Market Value (USD Million) (2025-2032) By Country

Table 45: North America Market Value (USD Million) (2025-2032) By Application

Table 46: North America Market Value (USD Million) (2025-2032) By Types

Table 47: Europe Market Value (USD Million) (2025-2032) By Country

Table 48: Europe Market Value (USD Million) (2025-2032) By Application

Table 49: Europe Market Value (USD Million) (2025-2032) By Types

Table 50: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 51: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 53: South America Market Value (USD Million) (2025-2032) By Country

Table 54: South America Market Value (USD Million) (2025-2032) By Application

Table 55: South America Market Value (USD Million) (2025-2032) By Types

Table 56: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 57: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 59: Research Programs/Design For This Report

Table 60: Key Data Information From Secondary Sources

Table 61: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

african trypanosomiasis treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	Africa
Country scope	Nigeria; South Africa; Egypt; Kenya; Ethiopia; Morocco; Ghana; Algeria; Tanzania; Ivory Coast
Key companies profiled	Merck & Co Inc; Novartis AG; Sanofi; Scynexis Inc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Regulatory complexities: Divergent approval pathways across African nations slow product commercialization, increasing time-to-market and operational costs for multinational companies.

Market Segmentation

Loading chart…

african trypanosomiasis treatment Segmentation Breakdown11 items

Application

Research Center

Hospital

Clinic

Others

Types

MS-08

CBL-0137

AN-5568

GNF-6702

Others

Regional Insights

Loading chart…

Key Drivers by Region5 items

Middle East & Africa: High endemicity, donor-funded programs (e.g., WHO), and mobile health clinics.

Europe: Fast-track regulatory policies, EU-funded R&D, and strong pharma-industry partnerships.

North America: Advanced diagnostic adoption, high patient awareness, and commercialization of new drug candidates.

Asia Pacific: Rising healthcare infrastructure investment, growing focus on neglected tropical diseases.

Latin America: Public-private partnerships, low-cost generic therapies, and cross-border disease monitoring.

Competitive Landscape

Merck & Co Inc: regional expansion in West African health corridors

Novartis AG: vertical integration of diagnostic and treatment pipelines

Sanofi: OEM tie-ups for low-cost generic drug production

Scynexis Inc: innovation pipeline targeting drug-resistant strains

Merck & Co Inc: public-private partnerships for disease surveillance

Novartis AG: cost optimization through bulk procurement contracts

Key african trypanosomiasis treatment Companies4 items

Merck & Co Inc

Novartis AG

Sanofi

Scynexis Inc

Market Ecosystem

Pharmaceutical manufacturers — produce first-line and second-line antitrypanosomal drugs

Raw material suppliers — provide active ingredients and excipients for drug formulation

Distributors — manage logistics and supply chain delivery to endemic regions

Regulatory bodies — establish safety, efficacy, and quality standards for treatment approval

Research institutions — conduct clinical trials and develop novel therapeutic agents

Non-governmental organizations — facilitate treatment access in low-resource endemic areas

Healthcare providers — administer treatments and monitor patient outcomes in field settings

Recent Industry Insights

Analyst Overview

Table of Contents